timothy sykes logo

Stock News

Crispr Therapeutics’ Stock Soars as Price Targets Rise

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 2/15/2026, 8:21 am ET 2/15/2026, 8:21 am ET | 5 min 5 min read
Crispr Therapeutics’ Stock Soars as Price Targets Rise Thumbnail

CRISPR Therapeutics AG stocks have been trading up by 8.05 percent driven by promising gene-editing advancements.

Healthcare industry expert:

Analyst sentiment – neutral

Market Position & Fundamentals: Crispr Therapeutics (CRSP) holds a precarious financial position, evidenced by a severe negative EBIT margin of -17094.9 and a profit margin of -16569.77. Total revenue stands at $3.51 million with a staggering Price to Sales ratio of 132.87, indicating severe overvaluation given its limited sales. The company’s reliance on equity financing, as seen from extensive stock issuances raising $111.49 million, highlights an unsustainable trajectory. Operating cash flows are negative at -$92.55 million, underscoring the financial pressure. Gross Profit of $163.29 million hints at some operational effectiveness, but persistent losses and a return on assets of -11.99 signal ongoing challenges in capital efficiency.

Technical Analysis & Trading Strategy: Recent weekly price patterns reveal a notable uptrend, with prices rallying from an opening of $48.3 to a close of $53.07. This progression suggests a bullish momentum, supported by the strong price surge and weekly high of $54.096. The presence of a higher low at $48.25 signifies strengthening support. Technical indicators favor a strategic short-term buy position with a target price of $54.50, while setting a stop-loss at $48.00. The trading strategy is bolstered by the considerable upward price action, reinforced by an anticipated increase in volume.

Catalysts & Outlook: Crispr Therapeutics has captured positive market attention, with analysts raising price targets, notably Chardan raising to $76 and Evercore ISI to $74. These revisions are driven by the promising potential of Casgevy, projected for significant revenue growth in 2026. ARK Investment’s acquisition of 120K shares indicates strategic interest in CRSP’s growth prospects. Nevertheless, the firm’s heel-dragging profitability and cash flow issues present significant concerns against the broader Healthcare and Biotechnology benchmarks. CRSP’s price target of $82, as per Needham’s recent rating, seems viable amid improving sales narratives. Immediate resistance is expected at $76, with support resting near $50. Anticipate positive price action tempered by operational hurdles.

Candlestick Chart

Weekly Update Feb 09 – Feb 13, 2026: On Sunday, February 15, 2026 CRISPR Therapeutics AG stock [NASDAQ: CRSP] is trending up by 8.05%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Crispr Therapeutics AG (CRSP) has shown a surge in its market valuation, supported by a series of analyst upgrades and strategic developments. Examining the recent stock price data, a noteworthy increase was observed, with the closing price jumping from $48.25 on February 12, 2026, to $53.07 by February 13, 2026. Such a rise reflects growing investor confidence catalyzed by new and optimistic financial guidance and product development promises.

Financially, the company faces substantial challenges reflected in negative profitability metrics — a pretax profit margin of -102.8% and an EBIT margin of -17094.9%, indicating high operational expenses relative to income. Despite these figures, Crispr Therapeutics benefits from an impressive current ratio of 13.3, suggesting substantial short-term financial health and capacity to handle obligations. The assets turnover indicates room for improvement in effectively utilizing its assets to generate revenue.

More Breaking News

Furthermore, the company’s financial reports reveal a substantial free cash flow deficit of $93.07M, indicating ongoing investment in operations and development. The revenue of $3.51M remains modest, but expectations hinge on large-scale growth, fueled by product innovations and potential market expansion routes. Strategic engagements like Vertex Pharmaceuticals’ guidance for Casgevy highlight a potential uptick in market confidence and revenue, fortifying a brighter horizon for CRSP.

Conclusion

In conclusion, Crispr Therapeutics is currently benefiting from increased analyst attention and stronger projections, resulting in a favorable outlook for its stock. While economic fundamentals such as profitability show room for improvement, the company’s strategic progress, especially in gene-editing innovations, provides a compelling case for traders focused on market growth potentials. The conjunction of heightened price targets, trading activity by significant players like ARK Investment, and promising product guidance injects optimism into the market narrative for CRSP’s trajectory. As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” Traders and analysts alike are watching closely, anticipating how these growth strategies will translate into tangible financial outcomes for Crispr Therapeutics.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”